Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).
1 finding from 1 review
Number of any adverse events: immediately after treatment · overactive bladder
1 finding from 1 review
Adverse drug events · people with ADHD and epilepsy
Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of people experiencing adverse drug events compared with risperidone and previous ASM only (low certainty).
1 finding from 1 review
Adverse drug events · people with ADHD and epilepsy
1 finding from 1 review
Number of participants reporting an adverse event · acute gout
Low‐dose colchicine showed no clear difference in total number of participants reporting adverse events compared with NSAIDs (low certainty).
1 finding from 1 review
Number of children with clinical adverse events (any) · children undergoing neurodiagnostic procedures
Chloral hydrate oral (100 mg/kg or 75 mg/kg) showed no clear difference in number of children with clinical adverse events (any) compared with midazolam (intranasal 0.2 mg/kg or oral 0.5 mg/kg) (low certainty).
1 finding from 1 review
Number of children with clinical adverse events (any) · children undergoing neurodiagnostic procedures
Chloral hydrate oral (50 mg/kg) showed no clear difference in number of children with clinical adverse events (any) compared with melatonin oral (low certainty).
1 finding from 1 review
Number of children with clinical adverse events (any) · children undergoing neurodiagnostic procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of children with clinical adverse events (any) · children undergoing neurodiagnostic procedures
Chloral hydrate oral (50 mg/kg or 100 mg/kg) may leads to higher number of children with clinical adverse events (any) compared with dexmedetomidine oral (2 µg/kg or 3 µg/kg) (low certainty).
1 finding from 1 review
Intervention not reported
Frequency of adverse events at two, six and 12 months · adults with newly diagnosed warm AIHA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (all adverse events) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
It is very uncertain whether rivastigmine changes adverse events (all adverse events) at 24 to 26 weeks compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (excluding deaths) at 26 weeks · vascular dementia and other vascular cognitive impairments
Galantamine showed no clear difference in serious adverse events (excluding deaths) at 26 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events at 4 weeks; 1085 participants (8 RCTs) · cervical dystonia
Botulinum toxin type A probably leads to higher adverse events at 4 weeks; 1085 participants (8 RCTs) compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.23 [1.05, 1.43]
Studies not reported
Moderate
Adverse events (hot flushes) · women with uterine fibroids
1 finding from 1 review
Intervention not reported
Adverse events: number of all types of adverse events · acute diarrhoea in children
The intervention showed no clear difference in adverse events: number of all types of adverse events (low certainty).
1 finding from 1 review
Serious adverse events or complications of treatments
It is very uncertain whether percutaneous nephrolithotripsy changes serious adverse events or complications of treatments compared with tubeless percutaneous nephrolithotripsy (very low certainty).
1 finding from 1 review
Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).
1 finding from 1 review
Adverse events including suicide and suicide ideation · Informal caregivers of adults with diagnosed illnesses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events including suicide and suicide ideation · Informal caregivers of adults with diagnosed illnesses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events at 15‐day · 10‐ to 26‐year‐old males
Three doses HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with control (high certainty).
1 finding from 1 review